{'fraction_non_alphanumeric': 0.029315960912052116, 'fraction_numerical': 0.006514657980456026, 'mean_word_length': 6.409638554216867, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Utility of FDG‐PET imaging in screening for succinate dehydrogenase B and D mutation‐related lesions

Mutations of the genes encoding succinate dehydrogenase B and D (SDHB, SDHD) are associated with highly penetrant phenotypes, including paragangliomas and phaeochromocytomas. Patients with these mutations require lifelong surveillance; however, there is currently ambiguity regarding the optimal screening regimen. We sought to determine the utility of fluorodeoxyglucose (18F) positron emission tomography (18F‐FDG PET) imaging, compared to other modalities for detecting SDHB and SDHD mutation‐related lesions.